The report assesses first-in-class innovation in the hematological cancer pipeline, highlighting key trends in first-in-class product distribution. Analysis reveals that the hematological cancer pipeline is among the most innovative in the industry, with 463 first-in-class products, representing 45.3% of the pipeline with a disclosed molecular target.
Browse Detail Report With TOC @
http://www.hexareports.com/report/frontier-pharma-hematological-cancers
The first-in-class targets in the pipeline are numerous and varied in nature. Cancer immunotherapies are the most common, with a total of 128 across all stages of development, followed by the signal transduction group of targets. The most commercially successful targeted drugs in the market fall into these two categories, including Rituxan (a cancer immunotherapy) and Gleevec (a signal transducer). The other target families have much fewer first-in-class products, reflecting the strong interest in cancer immunotherapies and targets implicated in signal transduction.
Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments have been based on the growing understanding of the signaling pathways involved in disease pathogenesis. A notable example is the approval of Rituxan in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma. Analysis indicates that the current pipeline is following this trend of focusing on innovative, targeted therapies.
Request A Sample copy of This Report @
http://www.hexareports.com/report/frontier-pharma-hematological-cancers/request-sample
Scope
* The hematological cancers market is characterized by commercially successful therapies.
o Which classes of drug dominate the market?
o What additional benefits have newly approved therapies brought to the market?
* The pipeline contains a range of molecule types and molecular targets, with a strong emphasis on targeted therapies, as opposed to chemotherapeutic agents.
o Which molecular targets appear most frequently in the pipeline?
o To what degree is the pipeline penetrated by first-in-class innovation?
o Which target families have the most first-in-class products?
* First-in-class products differ substantially in their clinical potential, based on their alignment to disease-causing pathways.
o How well are first-in-class targets aligned to known disease-causing pathways?
o Which targets are specifically found in early-stage development?
o Which are the most promising first-in-class targets in early-stage development?
Reasons to buy
1. Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
2. Visualize the composition of the hematological cancers market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
3. Analyze the hematological cancers pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating hematological cancers.
Browse More Pharmaceuticals & Healthcare Related Market Research Reports:
• Colorectal Cancer – Heat Map and Analysis -
http://www.hexareports.com/report/colorectal-cancer-heat-map-and-analysis
• Parkinson’s Disease – Heat Map and Analysis -
http://www.hexareports.com/report/parkinsons-disease-heat-map-and-analysis
• Non-Hodgkin Lymphoma – Heat Map and Analysis -
http://www.hexareports.com/report/non-hodgkin-lymphoma-heat-map-and-analysis
No comments:
Post a Comment